CLINICAL TRIALS PROFILE FOR LOTEMAX
✉ Email this page to a colleague
All Clinical Trials for LOTEMAX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00366691 ↗ | Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation | Completed | Medical University of South Carolina | Phase 4 | 2006-02-01 | The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan, Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery. |
| NCT00407043 ↗ | Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis | Completed | Bausch & Lomb Incorporated | Phase 4 | 2006-11-01 | To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy. |
| NCT00407043 ↗ | Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis | Completed | Ophthalmic Consultants of Long Island | Phase 4 | 2006-11-01 | To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy. |
| NCT00560638 ↗ | Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye | Completed | Bausch & Lomb Incorporated | Phase 2 | 2005-11-01 | This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization. |
| NCT00705159 ↗ | Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis | Completed | Bausch & Lomb Incorporated | Phase 4 | 2008-06-01 | The objective of this study is to evaluate the safety and effectiveness of Zylet in comparison with Lotemax, Tobramycin and the vehicle of Zylet for the treatment of blepharoconjunctivitis in pediatric subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOTEMAX
Condition Name
Clinical Trial Locations for LOTEMAX
Trials by Country
Clinical Trial Progress for LOTEMAX
Clinical Trial Phase
Clinical Trial Sponsors for LOTEMAX
Sponsor Name
